Triple

T6005131
Position Surface form Disambiguated ID Type / Status
Subject Tegsedi E133690 entity
Predicate hasActiveIngredient P12771 FINISHED
Object inotersen E561115 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: inotersen | Statement: [Tegsedi, hasActiveIngredient, inotersen]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: inotersen
Context triple: [Tegsedi, hasActiveIngredient, inotersen]
  • A. inotersen chosen
    Inotersen is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein.
  • B. Spinraza
    Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
  • C. Evrysdi
    Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
  • D. onasemnogene abeparvovec
    Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
  • E. Onpattro
    Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c00872444c8190bfaf1739dcec765c completed March 22, 2026, 3:19 p.m.
NER Named-entity recognition batch_69c04f10d18081908c351170b7f58d3d completed March 22, 2026, 8:20 p.m.
NED1 Entity disambiguation (via context triple) batch_69c11365741c819097a43a49dd2428c1 completed March 23, 2026, 10:18 a.m.
Created at: March 22, 2026, 4:06 p.m.